Pages
Products
Cre Adeno-associated virus(AAV Serotype 9)

Cre Adeno-associated virus(AAV Serotype 9)

Cat.No. :  AAV00048Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 9 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Gene Informationn

Cat. No. AAV00048Z
Description Cre Adeno-associated virus(AAV Serotype 9) which express Cre recombinase under the control CMV promoter. This product used in the Cre-lox system as a genetic tool to generate site-specific recombination of DNA between loxP sites in cultured cells and animal experiments.
Serotype AAV Serotype 9
Target Gene cre
Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Gene Name
Gene Symbol
Synonyms
Gene ID
Pathway
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Adeno-associated virus (AAV) vectors are derived from the non-pathogenic parvovirus family and are highly regarded for their ability to effectively deliver genetic material into a variety of cell types. AAV9 is known for its enhanced ability to cross the blood-brain barrier, which allows it to effectively target neurons and other cells in the central nervous system. This property makes AAV9 an excellent choice for gene therapy approaches to treat neurological diseases such as spinal muscular atrophy (SMA), Parkinson's disease, and Alzheimer's disease. When combined with Cre recombinase, a site-specific enzyme that recognizes and recombines DNA at loxP sites, AAV9 can achieve highly specific gene modifications. This system is widely used in conditional knockout studies, allowing researchers to selectively shut down specific genes in certain tissues or at specific developmental stages. By using Cre AAV9 vectors, scientists can unravel the complex gene functions and regulatory networks within the brain, elucidating pathways that may be critical to understanding neurodevelopmental and neurodegenerative diseases.

Adeno-associated virus (AAV) can penetrate the blood-brain barrier, but it is unknown whether AAV can penetrate other tight junctions. Genetic manipulation of the testis is hampered by the basement membrane of the seminiferous tubules and the blood-testis barrier (BTB), which forms between Sertoli cells and divides the tubules into basal and luminal zones. Here, researchers demonstrate in vivo genetic manipulation of spermatogonial stem cells (SSCs) and their microenvironment by AAV1/9. AAV1/9 microinjected into the seminiferous tubules can penetrate the basement membrane and the BTB, thereby transducing not only Sertoli cells and SSCs, but also peritubular cells and Leydig cells. Furthermore, when the testes of congenitally infertile KitlSl/KitlSl-d mice (deficient in Sertoli cells) were treated with AAV expressing Kitl, spermatogenesis was rejuvenated and offspring were produced. All offspring did not contain the AAV genome. Therefore, AAV1/9 can achieve effective germline and niche manipulation by penetrating the BTB and basement membrane, providing a promising strategy for developing gene therapies for reproductive defects.

Here, to study the transduction kinetics, the researchers used R26R-Eyfp mice, which allow for more sensitive identification of infected cells. They infected these mice with AAV9 expressing Cre. AAV9-Cre infection triggered the expression of EYFP, which was slightly stronger with tubular injection (Figure 1A). Immunostaining showed that WT1+ Sertoli cells were infected as early as 1 day after microinjection, while GFRA1+ spermatogonia showed no fluorescence (Figure 1B), indicating that Sertoli cell infection is a very rapid process.

Transduction Kinetics Analyzed by Microinjection of AAV9-Cre into R26R-Eyfp Mice.Figure 1. Transduction Kinetics Analyzed by Microinjection of AAV9-Cre into R26R-Eyfp Mice. (Watanabe S, et al., 2018)

AAV infection does not seem to significantly affect the SSC microenvironment, as real-time PCR showed that neither AAV1 nor AAV9 transduction affected the expression levels of cytokines involved in spermatogonia self-renewal and differentiation (Figure 1C). Since AAV1 and AAV9 penetrate into the BTB, the researchers examined the distribution of CLDN11, a major component of the BTB. However, CLDN11 expression was not significantly altered by AAV1 or AAV9 infection (Figure 1D). Three days after tubular or interstitial injection of AAV1 or AAV9-mCherry, biotin (557 D) was microinjected into the interstitium of adult testes. Cldn11 knockout (KO) mouse testes, which lack the BTB, were used as a positive control. Although leakage into the tubule lumen was readily observed in Cldn11 KO mice (Figure 1E), AAV injection did not induce significant leakage of biotin into the tubule lumen. These results indicate that both AAV1 and AAV9 penetrated the basement membrane and the BTB and infected Sertoli cells and germ cells.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Reliable Results

Its ability to cross the blood-brain barrier efficiently allows for precise targeting, enabling groundbreaking developments in our research on neurological disorders.

French

11/29/2024

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER